Shaky Support for the FDA’s Biologics Review
NegativeU.S News

Robert P. Charrow raises concerns about the FDA's review process for biologics, arguing that its efficacy review lacks a solid statutory foundation. This matters because the integrity of drug approvals is crucial for public health and trust in regulatory agencies.
— Curated by the World Pulse Now AI Editorial System










